The main purpose of the Developmental Research Program (DRP) of the Pacific Northwest (PNW) Prostate Cancer SPORE is to support innovative translational prostate cancer (PC) research pilot projects aimed at reducing the morbidity and mortality due to PC and at improving the survival and quality of life of PC patients. During the initial funding of the DRP, substantial progress has been made in the development and implementation of this unique and successful research program. During the first four years of the DRP, 46 pilot project proposals were submitted and 19 projects were funded (total of $798,100.00 direct funding). Ten publications and 7 grants have resulted to date from the DRP. For this continuation grant, the DRP program will continue to provide a mechanism to quickly respond to new translational research opportunities that may develop within the SPORE environments of participating institutions: Vancouver General Hospital (VGH) Prostate Centre in Vancouver, British Columbia, Canada;the University of Washington (UW), the Fred Hutchinson Cancer Research Center (FHCRC), and the Institute for Systems Biology (ISB) in Seattle, WA;and, Oregon Health Sciences University (OHSU) in Portland, OR. Support provided by the DRP will continue to allow innovative pilot projects to be initiated, with the expectation that the projects will mature sufficiently so that they can successfully compete for additional funding from sources either within or outside the SPORE grant. This program also attracts more senior investigators with diverse scientific expertise and new investigators into translational PC research.
The specific aims for the DRP are: 1) Solicit innovative, translational prostate cancer research study proposals for pilot funding on an annual basis; 2) Convene a panel of experts to provide rigorous scientific review of pilot study proposals following NIH guidelines for selection of the most promising research projects; 3) Provide pilot study funding for 1-2 years for the most innovative investigator-initiated ideas for research in all areas of prostate cancer research (including etiology, prevention, diagnosis, biological mechanisms, genetics, and treatment) with a special emphasis on projects that address issues relevant to advancing knowledge of disease aggressiveness or metastasis;and, 4) Allow the SPORE leadership to target funds to specific areas that are especially likely to advance the translational research goals of the PNW prostate cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-10
Application #
8330642
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2011-09-08
Budget End
2012-08-31
Support Year
10
Fiscal Year
2011
Total Cost
$184,960
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Inoue, Lurdes Y T; Lin, Daniel W; Newcomb, Lisa F et al. (2018) Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 168:1-9
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:

Showing the most recent 10 out of 400 publications